Valneva SE, a specialty Vaccinencompany, has signed an Advance Purchase Agreement (APA) with the nEuropean Commission (EC) to supply up to 60 million doses of its ninactivated COVID-19 vaccine candidate, VLA2001, over two years. The EC napproved the APA earlier this month.
Fareva Excella increases its production capacities of highly active products
Ebewe Pharma, ein Unternehmen der Novartis Gruppe, hat mit Fareva SA die Übernahme des Produktionsstandorts in Unterach (Oberösterreich) vereinbart. Wolf Theiss hat Fareva, ein Auftragsdienstleister im Pharma-Bereich, gemeinsam mit der französischen Anwaltskanzlei Darrois, bei den Verhandlungen des Kaufvertrages sowie der Nebenverträge beraten. Das Closing hat am 31. März stattgefunden.
Fareva, a prominent third-party manufacturer in the small molecule active pharmaceutical ingredient (API) and finished formulation space, entered the biologics sector last year through the acquisition of two facilities from fellow French firm Pierre Fabre.
Three COVID-19 vaccine manufacturing sites are set to start production in France in the coming weeks: while the French government is seeking to boost further production with a €300m ($363m) initiative announced on Monday.
Fareva, a world leader in the production of pharmaceuticals, and biopharmaceutical group MSD have finalised the disposal the Mirabel production site located in Riom, central France.
French CMO Fareva is looking to add four facilities and about 1,000 employees to build its sterile injectable and monoclonal antibody capacity.
Bayer joins Wacker and Fareva in CureVac’s COVID-19 vaccine network